Chemomab Therapeutics Ltd. Operating Cash Flow
Chemomab Therapeutics Ltd. (CMMB) reported Operating Cash Flow of -$11.13 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-23.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-03-23
- Chemomab Therapeutics Ltd. net cash provided by (used in) operating activities for the quarter ending 2023-06-30 was -$7.49M.
- Chemomab Therapeutics Ltd. net cash provided by (used in) operating activities for the quarter ending 2023-03-31 was -$7.19M.
- Chemomab Therapeutics Ltd. net cash provided by (used in) operating activities for the quarter ending 2022-12-31 was -$5.70M.
- Chemomab Therapeutics Ltd. net cash provided by (used in) operating activities for the quarter ending 2022-09-30 was -$5.25M.
- Chemomab Therapeutics Ltd. net cash provided by (used in) operating activities for fiscal 2020 was -$5.24M.
- Chemomab Therapeutics Ltd. net cash provided by (used in) operating activities for fiscal 2019 was -$16.46M.
- Chemomab Therapeutics Ltd. net cash provided by (used in) operating activities for fiscal 2018 was -$14.22M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | -$11.13M 20-F · filed 2026-03-23 | |||||||
| 2025-06-30 | -$6.14M 6-K · filed 2025-08-14 | |||||||
| 2024-12-31 | -$15.39M 20-F · filed 2026-03-23 | |||||||
| 2024-06-30 | -$7.19M 6-K · filed 2025-08-14 | |||||||
| 2023-12-31 | -$23.61M 20-F · filed 2026-03-23 | |||||||
| 2023-06-30 | -$7.49M derived: 6-K 6 month − 10-Q 3 month · filed 2024-08-21 | -$14.67M 6-K · filed 2024-08-21 | -$20.38M derived: sum of 3 quarters · filed 2025-04-04 | -$25.63M derived: sum of 4 quarters · filed 2025-04-04 | ||||
| 2023-03-31 | -$7.19M 10-Q · filed 2023-05-11 | -$12.89M derived: sum of 2 quarters · filed 2025-04-04 | -$18.14M derived: sum of 3 quarters · filed 2025-04-04 | -$23.84M derived: sum of 4 quarters · filed 2025-04-04 | ||||
| 2022-12-31 | -$5.70M derived: 20-F 12 month − 10-Q 9 month · filed 2025-04-04 | -$10.96M derived: sum of 2 quarters · filed 2025-04-04 | -$16.66M derived: sum of 3 quarters · filed 2025-04-04 | -$20.37M 20-F · filed 2025-04-04 | ||||
| 2022-09-30 | -$5.25M derived: 10-Q 9 month − 6-K 6 month · filed 2022-11-10 | -$10.96M derived: sum of 2 quarters · filed 2023-08-14 | -$14.67M 10-Q · filed 2022-11-10 | -$17.56M derived: sum of 4 quarters · filed 2024-03-28 | ||||
| 2022-06-30 | -$5.70M derived: 6-K 6 month − 10-Q 3 month · filed 2023-08-14 | -$9.41M 6-K · filed 2023-08-14 | -$12.31M derived: sum of 3 quarters · filed 2024-03-28 | -$14.89M derived: sum of 4 quarters · filed 2024-03-28 | ||||
| 2022-03-31 | -$3.71M 10-Q · filed 2023-05-11 | -$6.61M derived: sum of 2 quarters · filed 2024-03-28 | -$9.19M derived: sum of 3 quarters · filed 2024-03-28 | -$14.79M derived: sum of 4 quarters · filed 2024-03-28 | ||||
| 2021-12-31 | -$2.89M derived: 20-F 12 month − 10-Q 9 month · filed 2024-03-28 | -$5.47M derived: sum of 2 quarters · filed 2024-03-28 | -$11.08M derived: sum of 3 quarters · filed 2024-03-28 | -$12.37M 20-F · filed 2024-03-28 | ||||
| 2021-09-30 | -$2.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$8.19M derived: sum of 2 quarters · filed 2022-11-10 | -$9.48M 10-Q · filed 2022-11-10 | -$11.04M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | -$5.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$6.90M 10-Q · filed 2022-08-12 | -$8.46M derived: sum of 3 quarters · filed 2022-08-12 | -$9.36M derived: sum of 4 quarters · filed 2022-08-12 | ||||
| 2021-03-31 | -$1.29M 10-Q · filed 2022-05-12 | -$2.85M derived: sum of 2 quarters · filed 2022-05-12 | -$3.75M derived: sum of 3 quarters · filed 2022-05-12 | -$4.62M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | -$1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$2.46M derived: sum of 2 quarters · filed 2022-03-30 | -$3.33M derived: sum of 3 quarters · filed 2022-03-30 | -$5.24M 10-K · filed 2022-03-30 | -$12.71M 10-K · filed 2021-03-09 | |||
| 2020-09-30 | -$901.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$1.77M derived: sum of 2 quarters · filed 2021-11-12 | -$3.69M 10-Q · filed 2021-11-12 | -$11.02M 10-Q · filed 2020-11-16 | -$9.60M derived: sum of 4 quarters · filed 2021-11-12 | |||
| 2020-06-30 | -$873.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | -$2.79M 10-Q · filed 2021-08-13 | -$8.97M 10-Q · filed 2020-08-14 | -$8.70M derived: sum of 3 quarters · filed 2021-08-13 | -$12.21M derived: sum of 4 quarters · filed 2021-08-13 | |||
| 2020-03-31 | -$1.91M 10-Q · filed 2021-05-13 | -$3.54M 10-Q · filed 2020-05-07 | -$7.83M derived: sum of 2 quarters · filed 2021-05-13 | -$11.33M derived: sum of 3 quarters · filed 2021-05-13 | -$15.25M derived: sum of 4 quarters · filed 2021-05-13 | |||
| 2019-12-31 | -$5.91M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | -$9.42M derived: sum of 2 quarters · filed 2021-03-09 | -$13.34M derived: sum of 3 quarters · filed 2021-03-09 | -$16.46M 10-K · filed 2021-03-09 | ||||
| 2019-09-30 | -$3.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | -$7.42M derived: sum of 2 quarters · filed 2020-11-16 | -$10.54M 10-Q · filed 2020-11-16 | |||||
| 2019-06-30 | -$3.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | -$7.04M 10-Q · filed 2020-08-14 | ||||||
| 2019-03-31 | -$3.12M 10-Q · filed 2020-05-07 | |||||||
| 2018-12-31 | -$14.22M 10-K · filed 2020-03-17 |